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SUMMARY 
 
In order to control the illegal use of nitrofurans in food producing animals, an analytical method based 
on the detection of the side-chain molecules as marker residues has been in use. In analogy with 
furazolidone and its marker residue 3-amino-2-oxazolidinone (AOZ), semicarbazide (SEM) has been 
adopted as the marker residue for nitrofurazone. There is abundant evidence on the formation of 
semicarbazide from nitrofurazone (NFZ). Recently the confidence in SEM as an unambiguous marker 
residue has been questioned, due to the fact that alternative sources of SEM have been identified. 
Therefore, to ensure efficient and reliable control of nitrofurazone abuse, an alternative marker 
analyte, which can be unequivocally linked to nitrofurazone abuse, needs to be identified. For this 
purpose in this research project the following main objectives were defined: 
• Identification and structure elucidation of an alternative indicator (marker residue) for nitrofurazone 
use in animal derived food products 
• Development of a routine method of analysis to identify this marker that fulfils the requirements of 
Decision 2002/657/EC. 
 
Key to finding a new marker residue has been the study of the metabolism of nitrofurazone and the 
structure identification of the free metabolites most abundantly formed. In-vitro incubations were 
conducted using chicken liver microsomes and S9 fraction as well as Escherichia Coli ATCC 8739 
cultures. Two 14C radio-labelled analogs and a 13C,15N2-labelled stable analog of NFZ were 
synthesized to assist in the identification of metabolites. Owing to the fact that the synthesis of these 
standards was successful, the metabolic pathway of nitrofurazone could be elucidated in considerable 
detail. 
The combination of state-of-the-art high-resolution ToF mass spectrometry with MetAlignTM  software 
for analysis of  the full scan mass data proved very fruitfull in the detection and identification of a 
substantial number of metabolites. Based on the detected accurate mass elemental compositions 
could be derived for a number of potential metabolites. LC-MS/MS analysis of the incubates by means 
of neutral loss scanning yielded complementary information to LC-ToF-MS. Many of the metabolites 
detected by LC-ToF-MS were also identified by LC-MS/MS. MS/MS fragmentation yielded important 
information on the chemical structure of some of the newly identified metabolites.  
The major metabolite identifed was the cyano-metabolite. It was detected in all test systems and under 
all circumstances. In addition, two other interesting metabolites were identified: a low molecular weight 
metabolite (aminofurfural hydrazone) in microsome and S9 incubates and an amide metabolite in S9 
and E. Coli incubates. Several dimeric compounds were also detected in the microsome and E. Coli 
incubates, but these are of limited interest for in vivo systems. Furthermore, several cysteine and 
mercaptoethanol adducts were (tentatively) identified. However, these metabolites were only formed in 
detectable amounts when large amounts of the thiol component were added to the incubates. Based 
on the experiments conducted and the metabolites identified it can be concluded that several modes 
of metabolism occur simultaneously in the in vitro systems. The formation of the CN-metabolite is in 
good agreement with what is known from the metabolism of furazolidone and nitrofurazone. The CN-
metabolite could therefore be considered as a potential alternative marker for NFZ.  
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Analysis of incurred material showed unequivocally that the CN-metabolite is present in substantial 
amounts (approx. 500 µg/kg) in porcine muscle tissue during medication with nitrofurazone. In liver 
tissue the concentration was significantly lower. Probably the metabolite is quickly metabolised to 
other yet unidentified metabolites. Of the other metabolites selected, the aminofurfural hydrazone 
metabolite was qualitatively detected in incurred muscle tissue at zero withdrawal time. All other 
potential metabolites, if detected at all, were present in muscle as well as liver tissue only at low 
concentrations, even at zero withdrawal time. It could not be excluded that adducts are formed by 
reaction of thiol-containing substances (amino acids, gluthatione, proteins), but these adducts may be 
of limited stability under the extraction conditions used, or extraction recoveries for these compounds 
may be low. 
Accumulation of the CN-metabolite largely occurs in muscle tissue during medication. In muscle tissue 
it is detectable for at least one week after the end of medication. Although depletion in muscle tissue is 
relatively quick compared to the persistent tissue-bound adducts, its presence can be detected up to 
one week after the end of medication. It should be realized that many authorized veterinary drugs 
have depletion half-lives ranging from only a few hours up to a few days at the most. This is also the 
case for other banned substances like nitroimidazoles and various growth promoting agents.  
 
Overall it can be concluded that the main objective of the project, being “The identification and 
structure elucidation of an alternative indicator (marker residue) for nitrofurazone use in animal derived 
food products” has been completed successfully. The second objective, “Development of a routine 
method of analysis to identify this marker that fulfils the requirements of Decision 2002/657/EC”, could 
not be completed fully, due to the time-consuming procedure to elucidate the metabolic pathway of 
nitrofurazone. Nonetheless, the preliminary results obtained indicate that such a method can be 
developed for the CN-metabolite of NFZ. It is recommended that a future prolongation of this research 
should include improvement of the LC-MS/MS method for the CN-metabolite and that the substance 
should be made available as a reference material (including an isotopically-labelled analogue as IS). 
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1. INTRODUCTION 
 
Nitrofurazone is demonstrated to be in use in certain countries in shrimp farming and poultry 
production. However, this substance has been banned for use in animal production within the EU. Like 
the other nitrofuran antibiotics, it is readily available from numerous suppliers e.g. via the Internet in 
bulk quantities and at low price. Hence there is a clear risk of illegal use of this substance in the 
production of animal products intended for human consumption. Consequently the need for adequate 
control methods to detect the illegal use of nitrofurazone is evident.  
In order to control the illegal use of nitrofurans in food producing animals, an analytical method based 
on the detection of the side-chain molecules as marker residues has been in use. In analogy with 
furazolidone and its marker residue 3-amino-2-oxazolidinone (AOZ), semicarbazide (SEM) has been 
adopted as the marker residue for nitrofurazone.  
There is abundant evidence on the formation of semicarbazide (SEM) from nitrofurazone (NFZ) 
(McCracken et al, 2005). Recently the confidence in SEM as an unambiguous marker residue has 
been questioned, due to the fact that alternative sources of SEM have been identified (Becalski et al, 
2004, Stadler et al, 2004, Nooman et al, 2005). Therefore, to ensure efficient and reliable control of 
nitrofurazone abuse, an alternative marker analyte, which can be unequivocally linked to nitrofurazone 
abuse, needs to be identified. 
 
For this purpose the following main objectives were defined: 
• Identification and structure elucidation of an alternative indicator (marker residue) for nitrofurazone 
use in animal derived food products 
• Development of a routine method of analysis to identify this marker that fulfils the requirements of 
Decision 2002/657/EC. 
 
To achieve these objectives, the work was divided into 6 tasks: 
1. In-vitro techniques for metabolism studies 
2. Structure elucidation by advanced state-of-the-art mass spectrometric techniques of an 
alternative marker for nitrofurazone and further verification of the structure by using additional 
analytical instrumentation 
3. Conducting animal experiments for metabolism studies 
4. Synthesis of the pursued alternative marker 
5. Isolation and separation of residues at the µg/kg and sub-µg/kg level and development of an 
analytical method for the determination of an alternative marker compliant with CD 
2002/657/EC 
6. Reporting and dissemination of results 
 
Key to finding a new marker residue will be in the study of the metabolism of nitrofurazone and the 
structure identification of the most prominent free metabolites. For furazolidone such studies have 
been performed, resulting in the identification of a cyano-containing compound as one of the major 
 8 
metabolites (van Koten-Vermeulen et al, Vroomen et al, 1987a, 1987c, Abraham et al, 1984). In 
addition to that, protein-bound metabolites of furazolidone were identified which has eventually 
resulted in the banning of nitrofurans, but also in the current methodology to detect residues of 
nitrofurans.  
For the other nitrofurans including nitrofurazone, much less is known with regard to their metabolism. 
As mentioned, SEM has been chosen because of the resemblance of nitrofurazone to furazolidone 
and the experimental confirmation of the existence of SEM as a residue resulting from the treatment of 
animals with nitrofurazone. It is anticipated that a more detailed insight in the formation and identity of 
the major metabolites of nitrofurazone may offer opportunities to select another marker residue. Based 
on the information available on the metabolism of nitrofurazone, furazolidone and other nitrofurans an 
overview of potential metabolites of NFZ was made. This overview is presented in Annex I. Reduction 
of the nitro group by the action of nitroreductases is thought to occur in vitro as well as in vivo (De 
Angelis et al, 1999, Vroomen et al, 1987a, 1987b, 1987c, Abraham et al, 1984, Yeung et al, 1983). 
Reduction leads to the formation of aminofurazone, a reactive intermediate, that will quickly rearrange 
to a cyano-metabolite (CN-metabolite) (Yeung et al, 1983, Ebertino et al, 1962). The CN-metabolite is 
relatively stable and has been detected in urine of treated rats and swine (Vroomen et al, 1987c, 
Yeung et al, 1983).  An alternative reduction route has been postulated resulting in the formation of an 
acrylonitrile metabolite (AN-metabolite) (Vroomen et al, 1988, Vroomen et al, 1987b). This reactive 
intermediate can bind with thiol groups of peptides, amino acids and glutathione (Vroomen et al, 
1988). Furthermore, for furazolidone in some cases a dimeric compound has been observed in vitro 
systems (Vroomen et al, 1987a, Tatsumi et al, 1981). The relevance of dimeric compounds is 
considered to be very limited, as concentrations of NFZ used during medication will result in far lower 
levels in vivo than those applied in vitro. 
 
Furazolidone metabolism has been studied using a radio-labelled compound and identifying the major 
metabolites using radio-chromatography. Radio-labelled NFZ combined with radio-chromatography 
could be extremely helpful in identifying relevant substances that result from exposure of microsomes 
for further identification and structure elucidation. However, radio-labelled NFZ is not commercially 
available. Part of the research in this task will therefore aim at the synthesis of such a radio-labelled 
substance (Chapter 2).  
To perform a detailed study of nitrofurazone metabolism experiments using in-vitro techniques (e.g. 
liver microsomes and E. Coli cultures) will be conducted (Chapter 3). Cultures will be exposed to 
nitrofurazone and radio-labelled nitrofurazone to reveal differences in metabolism and in the formation 
of specific metabolites that could be useful in distinguishing nitrofurazone abuse from other sources of 
semicarbazide. Furthermore, cysteine and mercaptoethanol will be added to the incubates to 
determine whether these (in part endogenous) substances effect the metabolic pathway of 
nitrofurazone. 
Metabolites that are generated by means of the in-vitro techniques will be characterised using state-of-
the-art mass spectrometric techniques. As a first step chromatographic separation will be employed. 
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Incubates will be analysed using radio-chromatography as well as chromatographic separation 
combined with mass spectrometric analysis (LC-MS/MS and high resolution LC-ToF-MS). 
A stable isotope-labelled analog of NFZ will be synthesized and used in the incubations to determine 
the metabolic pathway. Dedicated software will be used for the comparison of full-scan spectra to 
identify specific differences in those spectra originating from microsome incubates with either native or 
isotope-labelled compound (Chapter 4).  
Once a candidate alternative marker residue is identified, a method of analysis should be elaborated. 
To determine whether the identified metabolites are present in incurred samples an analytical method 
will be developed. A number of standards of the identified metabolites has been provided by the 
partner involved in lot 2 (Eurofins, Germany). Due to their availability a straightforward extraction 
procedure and LC-MS method can be developed. (Chapter 5).  
To confirm whether the in-vitro metabolism complies with the in-vivo metabolism, incurred samples 
originating from animal studies performed by the partner involved in lot 3 (Chemical Surveillance 
Department, Veterinary Science Department, Belfast) will be analysed for the presence of the 
identified metabolites of nitrofurazone (Chapter 5).  
The report will conclude with the major results obtained by the research conducted in lot 1. Some 
recommendations for further study, directed towards the implementation of a confirmatory method 
using an alternative marker of nitrofurazone will be presented (Chapter 6). 
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2. PREPARATION OF RADIO ISOTOPE LABELLED AND STABLE ISOTOPE LABELLED 
NITROFURAZONE 
 
In the past the metabolism of furazolidone (FZD) has been studied using a radio-labelled analogue in 
combination with radio-chromatography to identify the major metabolites (Vroomen et al, 1987a, 
1987b, Abraham et al, 1984, Tatsumi et al, 1981). It was envisaged that the inclusion of radio-labelled 
NFZ in combination with radio-chromatography could be very helpful in identifying relevant 
metabolites, produced during exposure to microsomes or E. coli. Radio-labelled NFZ could also assist 
in the identification and structure elucidation by LC-MS. However, as a radio-labelled compound, NFZ 
is not commercially available, therefore it had to be prepared. The obtained radio-labelled NFZ was 
used for the in-vitro metabolic study of NFZ using microsomes and Escherichia coli (chapter 3). A 
stable isotope labelled isomer of NFZ was also included, in particular for the LC-MS studies of 
microsome and E. coli incubates. 
The isotopically labelled analogues of NFZ (Figure 1) that were synthesized, include a stable isotope 
labelled NFZ containing a carbon-13 and two nitrogen-15 atoms in the semicarbazide side-chain 
(NFZ-13C,15N2), and two radio-labelled NFZ analogs, containing a carbon-14 either at the methylidene 
carbon (NFZ-14Cmet) or at the semicarbazide carbon (NFZ-14Csem). Introduction of one carbon-14 atom 
increases the molecular weight with two mass units, while the molecular mass of the stable isotope 
analogue is increased with three units.  
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Figure 1: Chemical structure of NFZ and radioactive and stable isotope-labelled analogues. 
 
The synthesis of the stable isotope analog, NFZ-13C,15N2, was carried out by condensation of 
commercially available isotope-labelled SEM (SEM-13C,15N2, CSS, Belfast, UK) with 5-nitrofurfural (5-
NF) in dilute hydrochloric acid (Figure 2). NFZ-13C,15N2 was isolated in good yield (80%) and purity 
(>90%). Yield and purity were estimated by LC-MS analysis. 
SEM, containing a carbon-14 atom, is commercially available as well (ARC, St. Louis, USA). SEM-14C, 
with a specific activity of 40 mCi/mmol was reacted with 5 equivalents of 5-NF in dilute hydrochloric 
acid. After extraction with ethyl acetate, purification was performed on a Waters Sep-Pak plus silica 
cartridge. The product was dissolved in methanol. Yield (130 µg) and purity (65%) were estimated by 
means of LC-PDA-radio-chromatography and LC-MS analysis.  
 11 
The synthesis of NFZ containing the carbon-14 label at the methylidene position (NFZ-14Cmet) was 
conducted by side-chain exchange starting from 14C-labelled FZD (FZD-14Cmet), specific activity 44 
mCi/mmol). FZD-14Cmet was reacted with a large excess of SEM in dilute hydrochloric acid (Fig. 2). 
After extraction with ethyl acetate, purification was performed on a Waters Sep-Pak plus silica 
cartridge. The product was dissolved in methanol. Yield (75 µg) and purity (90%) were estimated by 
means of LC-PDA-radiometric analysis. In Figure 3 radio-chromatograms of NFZ-14Csem and NFZ-
14Cmet are shown.  
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Figure 2: Synthesis of the stable and radio isotope-labelled analogs of NFZ. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Radio-chromatograms of standard solutions of (a) NFZ-14Csem and (b) NFZ-14Cmet.  
a b 
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3. IN-VITRO TECHNIQUES FOR METABOLISM STUDIES 
 
3.1. In-vitro metabolic study of NFZ using chicken liver microsomes 
In-vitro techniques (e.g. incubates using liver microsomes) have been used to perform a detailed study 
of NFZ metabolism. For this purpose liver microsomes obtained from broilers were exposed to FZD 
and NFZ. Microsomes were isolated according to the procedure described by Vroomen et al. (1987a, 
1987b). FZD was included in the experiments, for the purpose of comparison.  
Microsome incubates use ß-nicotinamide adenine dinucleotide phosphate (NADPH) as cofactor. In the 
initial experiments a large background signal for SEM was observed in the LC-MS/MS analysis of the 
positive as well as in the control samples. A detailed investigation was carried out to locate the origin 
of this background signal. Eventually, the source of the SEM background could be pinpointed to a 
specific batch of NADPH. When a different batch of NADPH was used, the background of tissue-
bound SEM originating from NADPH was only 0.1% of the total tissue-bound SEM.  
Tests were conducted to optimise the experimental conditions of the microsome incubates, in 
particular the incubation time, the concentration of NFZ and the amount of microsomes. Incubates 
were analysed for NFZ and for tissue-bound SEM by LC-MS/MS. The results are presented in Figure 
4. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. (a) Decrease of NFZ and (b) formation of tissue-bound semicarbazide (TB SEM) during the 
incubation of microsomes (arbitrary units). 
 
From Figure 4 it is evident that the concentration of tissue-bound SEM reaches a plateau after 
approximately 60 minutes of incubation at 37°C. There is however only a 10-15% decrease in NFZ 
concentration in the incubate mixture. Apparently the microsomes become inactivated after 60 min and 
the conversion to metabolites stops. Increasing one or more of the ingredients of the incubate mixture 
did not result in a significantly improved conversion. The procedure presented below describes the 
optimum conditions for the in-vitro microsomal metabolism of NFZ.  
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Microsomal incubation 
A standard incubation mixture was prepared by mixing 3 mM MgCl2 (750 µl), 0.1 M potassium phosphate buffer, 
pH 7.4 (600 µl) and 500 µl of a freshly thawed chicken liver microsome suspension (containing ca. 2.5 mg 
protein). Freshly prepared 1mM NADPH (100 µl) was added to the mixture. The incubation mixture was pre-
incubated at 37°C for two minutes. Incubation was started by the addition of NFZ (20 µg) dissolved in methanol 
(50 µl). The final volume was 2 ml. After incubation for 60 minutes at 37°C the reaction was terminated by the 
addition of ice-cold methanol (1 ml) or by cooling the incubation tube using ice. 
 
Additionally, incubations were also carried out using the complete S9 liver fraction incubates. This 
fraction contains more liver cells and proteins and can therefore result in additional metabolites or 
adducts compared to the microsome incubates.  
 
3.2. In-vitro metabolic study of NFZ using E. Coli incubates 
In the past FZD exposed to Escherichia Coli ATCC 8739 has been used to study its metabolism 
(Abraham et al, 1984). In order to determine whether E. Coli could be helpful in the search for an 
alternative marker residue for NFZ, incubations with NFZ were carried out. To 10 ml of freshly 
prepared E. Coli culture 100 µg of NFZ or FZD (for comparison) was added and the mixture was 
incubated at 37°C. Aliquots were taken at different points in time (0 – 15 – 30 and 60 minutes) and 
extracted using ethyl acetate. The ethyl acetate fractions were evaporated and redissolved in mobile 
phase. The samples were analysed by LC-MS/MS for the presence of NFZ and the cyano-metabolite 
(CN-metabolite). The results are shown in Figure 5. A rapid metabolism of NFZ occurred resulting in 
the almost complete disappearance of this drug after 1 hour. At the same time the formation of the CN-
metabolite as a prominent component is evident.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: (a) Decrease of NFZ and (b) formation of the cyano-metabolite during the E. Coli ATCC 8739 
incubation (arbitrary units). The results are based on the analysis of the ethyl acetate fractions. 
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At the time these E. coli experiments were conducted, a synthesized standard of the CN-metabolite 
was not available yet. Identification was based on LC-MS/MS data and on analogy with the formation 
of a CN-metabolite in the metabolism of furazolidone in E. Coli incubates. The samples were analysed 
using tentative precursor-fragment ion transitions for the presumed CN-metabolite. Later on the 
identity of the CN-metabolite in E. Coli as well as microsome incubates was confirmed by means of 
comparison with a chemically synthesized standard, kindly provided by Dr. S. Weigel and Dr. R. 
Gatermann (Eurofins, Hamburg, Germany). 
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4. STRUCTURE ELUCIDATION OF NITROFURAZONE METABOLITES 
In the search for a potential marker residue of NFZ-metabolism, the detection and structure-elucidation 
of potential metabolites forms an essential part of research. To achieve the identification of metabolites 
several techniques were applied: 
1. Analysis of radio-labelled NFZ incubates by means of radio-chromatography.  
2. Analysis of incubates of NFZ, radio-labelled NFZ and stable isotope-labelled NFZ for the presence 
of metabolites using LC - Time of Flight - mass spectrometry (LC-ToF-MS) in combination with 
MetAlignTM data processing software. 
3. Analysis of incubates of NFZ in combination with stable isotope-labelled NFZ for the presence of 
metabolites using LC – tandem – mass spectrometry (LC-MS/MS). 
 
In Table 1 an overview is given of the standards, test systems and detection techniques which have 
been used in this study to generate, identify and elucidate metabolites of nitrofurazone, that could 
serve as alternative markers for semicarbazide. The radio-isotope labelled analogs have been 
incubated in the three in-vitro systems and analysed by radio-chromatography and by LC-ToF-MS. 
Nitrofurazone and its stable-isotope analogue have been metabolised in the same three test systems, 
in the absence and in the presence of cysteine or mercaptoethanol. Detection and identification of 
metabolites in these incubates has been performed by LC-ToF-MS and LC-MS/MS techniques. The 
synthesized standards have been incorporated to assist in the identification of potential metabolites. 
 
Table 1: Overview of the relevant compounds, test systems and detection techniques used in this 
study 
Compounds In-vitro test 
systems 
Addititives Detection 
Techniques 
Synthesized standards 
NFZ 
13C15N2-NFZ 
Chicken liver 
microsomes, S9   
E. Coli ATCC 8739 
Cysteine 
Mercaptoethanol 
LC-ToF-MS 
(MetAlign)   
LC-MS/MS 
(neutral loss and 
MS/MS) 
Cyano-metabolite 
Acrylonitrile-metabolite 
Cysteine-cyano-
metabolite 
Gluthatione-cyano-
metabolite 
     
14C-NFZmet 
14C-NFZsem 
Chicken liver 
microsomes, S9   
E. Coli ATCC 8739 
 Radio-
chromatography 
LC-ToF-MS 
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4.1 Radio-chromatography 
Radio-chromatography is used to identify the fractions of the chromatogram that contain NFZ 
metabolites. Furthermore, LC-radiometry can provide information about the relative amounts and the 
polarity of the metabolites formed during in vitro experiments.  
 
4.1.1 Applied methodology 
Extracts of microsomal, S9 and E. Coli incubates exposed to 14C-NFZsem or 14C-NFZmet were produced 
and analysed by LC-radiometry as described below.  
 
LC-Radiometric analysis of microsome and E. Coli incubates 
Extracts of microsome and E. Coli incubates obtained according to the protocols described in section 3.1 and 3.2 
were injected into the LC-PDA-Radiometric system equipped with a Chrompack Hypersil 5 ODS column (25 x 4.6 
mm, 5 µm). A gradient changing from 2% to 90% acetonitrile in water-1.0M acetate buffer pH 5.0 was used at a 
flow of 1 ml. The PDA detector (Waters991) was set at 254 nm. Ultima Flo M (Packard bioscience) was added 
post column as scintillation reagent at 3.5 ml/min. After mixing with the column effluent, the beta-radiation was 
measured with a flow counting detector (Berthold LB 506C). 
 
Inspection of the radio-chromatograms enabled identification of fractions containing possible 
metabolites of NFZ. The next step was to collect fractions of the incubates for detailed analysis by LC-
MS. However, the addition of scintillation fluid to the LC-eluent, necessary to perform the radiometric 
detection, prohibited the in-line collection of fractions. Alternatively, fractions were collected with a LC-
fractionation system (Hewlet Packard, HP1100) using a Novapak C18 (150 x 3.0 mm, 5 µm) analytical 
column at a flow of 400 µl/min. Gradient elution was applied from 0 to 90% acetonitrile in 31 minutes. 
Aliquots of 100 µl were injected on the fractionation system and fractions of 1 min were collected. The 
fractions collected were analysed by UPLC-ToF-MS to identify potential metabolites of NFZ (section 
4.1.2). 
 
4.1.2 Results and Discussion 
Radio-chromatograms of microsome incubates with the two 14C-NFZ radio-labelled compounds are 
presented in Figure 6. The results show that incubates to which 14C-NFZmet was added contained more 
and higher concentrations of metabolites than the incubates containing 14C-NFZsem. Considering also 
the fact that the purity of 14C-NFZmet is much better (Chapter 2) it was decided to conduct additional in-
vitro experiments solely with 14C-NFZmet. From Figure 6 it can be seen that several metabolites are 
produced. The peak eluting at 12.1 min could be attributed to the CN-metabolite. 
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Figure 6: Radio-chromatograms of (a) a chicken liver microsome incubate containing 14C-NFZmet and 
(b) an incubate containing 14C-NFZsem. 14C-NFZmet and 14C-NFZsem elute at 28.4 minutes and the CN-
metabolite at 12.1 min. The peak eluting at 25.3 min in the 14C-NFZsem incubate is not a metabolite but 
an impurity present in the starting material. 
 
In Figure 7 a radio-chromatogram of an E. Coli and a S9 incubate with addition of 14C-NFZmet is 
presented. The extracts were analysed under slightly different chromatographic conditions compared 
to the microsome incubates given in Figure 6, resulting in somewhat reduced retention times.  Under 
these conditions 14C-NFZmet eluted at a retention time of 22.2 min. Compared to the radio-
chromatogram of the microsome incubates, a much larger decrease of the 14C-NFZmet signal was 
observed in the S9 and even more prominently in the E. Coli incubates. The observation for the E. Coli 
incubate is in close agreement with the results obtained during the optimisation of the E. Coli 
incubation procedure (chapter 3). These results indicate a more efficient metabolism using E. Coli 
compared to microsomes. Furthermore, according to the radio-chromatogram, the E. Coli incubation 
with NFZ produces one major peak at a retention time of 8.2 min. In analogy to the predominant 
formation of a CN-metabolite from furazolidone and furaltadone in E. Coli incubates (Vroomen et al, 
1987c, Hoogenboom et al, 1994) and taking into account the results obtained during the optimisation 
process described in section 3.2, this peak can be attributed to the CN-metabolite of NFZ.   
The radio-chromatogram of the S9 incubate also shows a significant decrease of 14C-NFZmet. A small 
peak is observed at RT = 8.2 min., very likely corresponding to the CN-metabolite. Furthermore, the 
majority of radioactivity elutes at very short retention times (< 6 min.), indicating the formation of highly 
polar metabolites in S9 incubates.  
 
 
 
 
 
 
 
 
a b 
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Figure 7: Radio-chromatograms of (a) an E. Coli incubate containing 14C-NFZmet and (b) a S9 incubate 
containing 14C-NFZmet. 14C-NFZmet elutes at 22.2 minutes and the CN-metabolite at 8.2 min. 
 
Following the radio-chromatography results, several incubates were fractionated. These fractions were 
analysed for metabolites of NFZ using LC-ToF-MS (section 4.2). Unfortunately, fractionation resulted in 
rather diluted sample extracts, which in practise prevented the detection and identification of all except 
the most prominent metabolites. Furthermore it proved difficult to ‘translate’ the chromatographic 
conditions of the LC-PDA-radiometric system to that of the LC-PDA-fractionation system. This was 
due to the fact that both systems have rather different dimensions (column size, eluent flow, dead 
volumes, etc). As a result the fractionation envisaged could not be achieved with the LC-fractionating 
system. Considering the complications encountered it was decided not to proceed in this direction, but 
instead to analyse the complete extracts of incubates directly.  
 
4.2 LC-ToF-MS 
For the detailed analysis of incubates of NFZ, LC-ToF-MS in combination with MetAlignTM software 
provides a powerful combination. Comparison of the full scan mass data obtained for blank incubates 
with incubates to which native NFZ, radio-labelled or stable-isotope labelled NFZ has been added, 
may lead to the identification of potentially interesting metabolites. The analysis of these full scan data 
will result in elementary compositions generated for metabolites. The availability of an elementary 
composition will assist in the assignment of a chemical structure to an unknown metabolite.  
Compounds containing thiol groups (glutathione, cysteine, mercaptoethanol, proteins) have been 
implicated to react with the acrylonitrile metabolite to form conjugates (Vroomen et al, 1987c). Adding 
an excess of a thiol-containing compound may have a significant effect on the metabolism of NFZ, as 
it may direct the system towards the production of the corresponding sulphur-containing adducts. In 
this study the formation of thiol-containing metabolites was simulated by the addition of cysteine and 
mercaptoethanol to the reaction mixture. 
 
 
a b 
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4.2.1 Applied methodology 
Freshly prepared extracts of microsome, E. Coli and S9 incubates of NFZ, 14C-NFZmet, 13C15N2-NFZ or 
a mixture of NFZ and 14C-NFZmet were analysed using LC-ToF-MS in positive as well as negative 
electrospray mode. The experimental conditions are described below. 
 
LC-ToF-MS analysis of microsome, S9  and E. Coli incubates 
Extracts of microsome, S9 and E. Coli incubates were obtained according to the protocols described in section 
3.1 and 3.2. 10-20 µl aliquots were injected into the LC-ToF-MS system. Two different types of column were 
applied for chromatographic separation. 
In the first method a Waters Acquity C18 (50 x 2.1 mm, 1.7 µm) column was used at a flow rate of 200 µl/min. The 
metabolites were separated using a linear gradient changing from 100% water to 90% acetonitrile in 19 minutes. 
With this method NFZ was observed at a retention time of 12 minutes and the CN-metabolite at 6 minutes. 
The second method was developed specifically for the separation of more polar compounds and consisted of a 
Waters Atlantis C18 (150 x 2.1 mm, 3 µm) column, operated at a flow rate of 200 µl/min. The metabolites were 
separated using a linear gradient changing from 100% water to 90% acetonitrile in 22 minutes. With this method 
NFZ was observed at a retention time of 23 minutes and the CN-metabolite at 16 minutes. 
In both methods water and acetonitrile of LC-MS quality (Biosolve, Valkenswaard, the Netherlands) was used to 
reduce background interferences. 
ToF-MS settings: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The LC-ToF-MS is capable of collecting full scan data at high resolution (>10.000 in W-mode). 
Typically, datasets of several gigabytes are produced during an overnight run. For the interpretation of 
these data sets specialized software is required which removes interferences and reduces the amount 
of data produced. MetAlignTM software is a program specifically designed to perform these tasks (see 
below). 
 
 
 
 
Parameter Positive mode Negative mode 
Ionisation technique ESI ESI 
Capillary voltage (kV) 2.0 3.0 
Sample cone (V) 35 35 
Desolvation temperature (°C) 450 450 
Source temperature (°C) 120 120 
Cone gas flow (l/h) 50 50 
Desolvation gas flow (l/h) 450 450 
Mode (resolution,  FWHM) W (>10000) W (>10000) 
Scan time (s) 0.5 0.5 
Lock mass Sulfadiazine (m/z=251.0603) Sulfadiazine (m/z=249.0480) 
Attenuated lock mass Sulfadimethoxine (m/z=311.0814) Sulfadimethoxine (m/z=309.0658) 
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MetAlign™ (www.metalign.nl) has been designed to distinguish between and filter out statistically significant 
differences between pre-defined classes of full scan LC or GC mass spectrometry data sets.  As such, MetAlign™ 
has broad application in the fields of metabolomics, pharmaceuticals (lead and target identification), 
agrochemicals (lead identification, mode of action analysis), biological science (biochemical profiling, breeding), 
food processing (quality control, substantial equivalence) and GM product analysis (substantial equivalence). 
 
MetAlignTM can be used to identify differences between the chromatograms of blank incubates and 
incubates of NFZ. Examples of MetAlignTM output are given in Figures 8 and 9. In Figure 8 total ion 
current (TIC) chromatograms are given of an E. Coli incubate of NFZ, a blank E. Coli incubate and the 
corresponding MetAlignTM output. In this example the difference between the TIC chromatograms is 
quite clear. However, the chromatograms of incubates of microsomes show a very different situation 
(Figure 9) and indicate the necessity of using MetAlignTM to pinpoint the relevant differences. The 
compound(s) linked to a specific difference can be identified by further processing of the full scan data.  
 
 
Figure 8. Section of the TIC chromatograms (pos ESI) of (a) an E. Coli incubate of NFZ, (b) a blank E. 
Coli incubate and (c) the corresponding MetAlignTM output indicating a major difference at RT = 15.8 
min. Chromatograms have been obtained with LC-MS gradient method 2. 
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Figure 9. Section of the TIC chromatograms (pos ESI) of (a) a microsome incubate of NFZ, (b) a blank 
microsome incubate and (c) the corresponding MetAlignTM output indicating several significant 
differences. Chromatograms have been obtained with LC-MS gradient method 2. 
 
An example of the procedure depicted is presented in Figures 9 and 10. Using MetAlignTM, the TIC 
chromatograms (representing full scan data!) of the blank and NFZ microsome incubate (Figure 9) 
have been processed and the significant differences are shown in the lower trace.  Each difference 
present in this trace has been investigated. For instance, the mass spectrum corresponding to the 
peak at RT=15.5 min of Figure 9 is shown in Figure 10. From the full scan data the single ion 
chromatograms can be extracted. This has been done for the m/z=169 ion trace of the blank and NFZ-
microsome incubates as an example. The single ion chromatograms show the presence of a 
compound with mass of 169 (as protonated molecular ion) in the NFZ-incubate at the selected 
retention time. Finally the high resolution mass spectrum of the selected peak at RT=15.5 is depicted, 
revealing the accurate mass of the selected compound. 
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Figure 10. Procedure for the determination of the exact mass of an unknown compound showing (a) 
the spectrum of the MetAlignTM output obtained from the Total Ion Current chromatograms presented 
in Figure 9 corresponding with the peak at RT=15.5 min, (b) the single ion chromatogram (m/z=169) of 
the microsome incubate of NFZ showing the peak of the unknown compound, (c) the single ion 
chromatogram (m/z=169) of the blank microsome incubate and (d) the mass spectrum of the selected 
peak at RT=15.5 showing the accurate mass of the unknown compound. 
 
The final step in the identification of unknown compounds is to work out possible elemental 
compositions (molecular formulas) by using the Masslynx 4.0 software. To this end possible elements 
(C, H, O, N, S, Na, K) and specific ranges for each element, as well the maximum allowed mass error 
have to be included. Under normal circumstances the instrument operates with a mass error of 5 ppm 
or less. However, to make sure no metabolites are overlooked the maximum allowed mass error has 
been set at 10 ppm. An example of the output of the calculation of possible elemental compositions is 
presented in Figure 11. The combined information on the retention time, the accurate mass and the 
calculated elemental compositions can be used to carry out a tentative identification. 
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Figure 11: Masslynx elemental composition output indicating the possible elemental compositions with 
a theoretical mass within a given range of 10 ppm from the experimentally determined mass. As an 
example the output is shown for the component selected in Figure 10.  
 
The determination of an accurate high resolution mass and (a list of) elemental composition(s) in many 
cases may not be sufficient to derive a chemical structure for a particular component. An additional 
problem occurs for components observed at elevated molecular weights. The theoretical number of 
possible elemental compositions increases exponentially with increasing mass.   
However, additional information whether an unknown compound originates from NFZ or not can be 
obtained by comparing the obtained mass data of the native NFZ incubate with corresponding 
metabolites and degradation products originating from radio-labelled NFZ incubate and the stable-
isotope labelled NFZ incubate. The presence of a 14C-atom in 14C-NFZmet produces a mass difference 
of 2.0032 units with that of native NFZ, while the isotopes present in 13C15N2-NFZ will yield a mass 
difference of 2.9974 units. If a component is detected in the incubates of NFZ, 14C-NFZmet and 13C15N2-
NFZ at identical retention time and with correct theoretically predicted mass increments it is a 
compound highly likely to originate from NFZ. An example is presented in Figure 12. 
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Figure 12. Corresponding single ion chromatograms of the E. Coli incubates of (a) NFZ, (b) 13C15N2-
NFZ and (c) 14C-NFZmet. The presence of a peak in each of the chromatograms of the NFZ incubates, 
at the same retention time and at a mass matching the predicted elemental composition and mass 
increments, is highly indicative for a metabolite originating from NFZ. 
 
The mass increase for metabolites originating from labelled NFZ, will only be observed if the labelled 
atoms are still present in the metabolite. Hence, the results obtained for the NFZ-13C15N2 incubate will 
provide information about the presence (or absence) of the SEM side-chain in the unknown molecule, 
whereas the presence or absence of the methylidene carbon in the unknown compound can be 
concluded from the results of the NFZ-14Cmet incubate. Likewise, wehn dimeric products are formed, 
this is reflected in a double increment of the molecular mass in the isotopically labelled analogs. 
 
4.2.2 Identification of metabolites by LC-ToF-MS 
Analysis of the chicken liver microsomal, S9 and E. Coli incubates by LC-ToF-MS (positive and 
negative electospray mode) resulted in numerous full scan chromatograms. Hundreds of differences 
were indicated by comparing blank incubate full scan chromatograms with corresponding NFZ 
incubate full scan chromatograms using MetAlignTM software. Most differences were only found once 
and were therefore not consistent over replicate analyses. Those differences were considered as 
artefacts. 
For the remaining, consistent differences, the accurate mass was determined resulting in a list of 
possible metabolites for every type of incubate for both positive and negative mode analysis. Typically 
these ‘extended’ lists contained 10 to 30 candidate compounds. For each candidate compound 
possible elemental compositions were calculated that fitted with the accurate mass determined. Some 
of those calculations resulted in unrealistic elemental compositions (e.g. C2H18NS) and based on the 
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accurate mass, no further link to the theoretical metabolism of NFZ could be made. These candidate 
compounds were not investigated further.  
Under the experimental conditions, in positive mode the metabolites were most commonly detected as 
protonated molecular ions (theoretical molecular mass + 1.0078 Da), but sometimes as their sodium 
(+ 22.9898 Da) and potassium (+ 38.9637 Da) adducts as well. On some occasions (partial) in-source 
fragmentation was observed. The formation of protonated ammonia (+ 18.0338 Da) or acetonitrile (+ 
42.0038 Da) adducts was also observed. In negative mode the deprotonated molecular ion (theoretical 
molecular mass - 1.0078 Da) in general was the most prominent and little or no in-source 
fragmentation was observed.   
Information regarding the presence of the SEM side-chain and the methylidene carbon in the 
remaining candidate metabolites was derived by comparison of the NFZ incubate with the labelled 
NFZ incubates. A list of metabolites (tentatively) identified by LC-ToF-MS is presented in Table 2 and in 
Annex II. Of the metabolites listed, only the presence of the CN-metabolite could be confirmed in all 
incubates.  
 
Table 2. The theoretical mass, retention time and suggested identity of NFZ metabolites obtained by 
LC-ToF-MS in the microsome, S9 fraction and E. Coli incubates.  
Retention time (min) Microsome 
S9 fraction 
E. Coli 
Theoretical 
mass (m/z) 
gradient 1 gradient 2 
Positive / 
Negative 
ESI 
SEM side-
chain 
Suggested 
elemental 
composition 
Suggested identity 
M, S, E 168.065 5.9 15.8 P + N Single C6H8N4O2 Cyano-metabolite 
M, S 316.103 6.5, 10.3 16.3, 18.1 P + N Double C12H12N8O3 Dimeric compound 
M, S 366.104 10.2, 11.1   P + (N) Double C12H14N8O6 Dimeric compound, 
mono-nitro derivative? 
E 187.059  6.3 P Single C8H9N3O4 Carboxylic acid 
metabolite (trace) 
E 332.098 11.2  N Double C12H12N8O4 Dimeric compound 
 
A number of different dimeric compounds was formed in these incubates; the most important are listed 
in Table 2. The structures of these dimeric compounds remain highly speculative. Moreover, each 
structure may be present in the incubates in more than one isomeric form. Additional information 
(NMR, MS/MS fragmentation) will be required to propose a molecular structure for these compounds. 
However, some remarks can be made here. For instance, the dimeric compound with mass 366 
present in microsomal and S9 incubates may be related to a similar dimer that has been found in 
furazolidone incubates. The dimer reported in rat liver microsome incubates (Tatsumi et al, 1981 and 
Vroomen et al, 1987a, 1987b) was thought to originate from the condensation of furazolidone and its 
corresponding acrylonitrile metabolite (AN-metabolite). However, the metabolite described also 
contained an additional hydroxyl group, which would in case of nitrofurazone result in a mass of 382. 
The structure of the furazolidone dimer proposed (Tatsumi et al, 1981), was mainly based on its 
elementary composition and proton NMR spectrum; no mass spectra of this metabolite could be 
obtained at the time.  
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In the microsome and S9 incubates of nitrofurazone two other dimeric compounds - with mass 316 - 
are present, which do not seem to have an equivalent with the studies on furazolidone. These 
metabolites are formed abundantly in the incubates and they are observed in positive as well as in 
negative electrospray mode. The derived elemental composition and the information obtained from the 
isotopically-labelled analogs (the presence of two SEM side-chains) suggests a dimeric compound 
formed by condensation of an acrylonitrile metabolite and the CN-metabolite or the amino metabolite, 
followed by loss of an oxygen atom in the form of water. The proposed structure remains highly 
speculative, however. In E. Coli preparations the above mentioned dimers could not be detected.  
Instead, another dimeric compound (mass 332) is present in low concentrations. Dimeric compounds 
may occur in in vitro incubates due to the relatively high concentration of nitrofurazone in these 
systems. There is little chance, howerer, that in vivo these dimers will be detected, because NFZ 
concentrations are much lower.    
 
Even with gradient 2 and the high polarity Waters Atlantis column, the possibility remains that one or 
more polar metabolites escape detection by LC-ToF-MS. According to the radio-chromatograms of the 
various incubates, there may be several polar metabolites eluting very early in the chromatogram. 
However, many other interfering matrix components elute in this region, making the selection and 
identification of potential metabolites by means of ToF-MS rather difficult.  
 
When excess cysteine or mercaptoethanol is added to the incubates, this has a pronounced effect on 
the metabolic pathways and as a result many new metabolites have been identified (Table 3). In 
general the CN-metabolite is still present in these incubates, although in somewhat reduced amounts 
(especially when cysteine is added). Perhaps more striking is the observation that dimerisation is 
strongly suppressed, only trace amounts can be found in some of the microsome incubates.  
 
Addition of cysteine to the incubates produces at least three different cysteine adducts. Some tentative 
structures are presented in Annex III. The cysteine metabolite with mass 287 detected in the E. Coli 
preparations is very likely the same compound as the cysteine-cyano-metabolite synthesized by 
Eurofins (section 4.3.3). The theoretical mass, suggested elemental composition and retention time all 
matches each other. In microsome and S9 preparations this metabolite is probably produced in trace 
amounts only. Instead, two new cysteine containing metabolites are observed, with MW 288 and 290, 
respectively. The elemental compositions calculated for these compounds (Table 3) indicate the 
presence of a cysteine adduct. Furthermore, based on the mass increment in the corresponding 
13C15N2- analogs it is clear that the SEM side-chain is still intact in these metabolites. The mass 
difference of 1 and 3 units with the cysteine-cyano-metabolite synthesized provides an indication that 
one of the nitrogen atoms has been lost. According to the calculated elemental compositions this 
nitrogen atom has been replaced by an oxygen atom. At the moment the most likely explanation is that 
the nitro (or amino) group of the furan ring is attacked by the thiol group and, subsequently after ring 
opening and addition of water, a thioester is formed (see Annex III). 
 27 
Table 3. The theoretical masses, retention times and suggested elemental composition of the 
metabolites found in the microsome, S9 and E. Coli incubates in the presence of excess cysteine and 
mercaptoethanola  
     
Retention time (min) 
Microsome 
S9 fraction 
E. Coli 
Addition of 
Cysteine / 
Mercapto-
ethanol 
Theoretical 
mass (m/z) 
Gradient 1 Gradient 2 
Positive/ 
Negative 
mode 
Suggested 
elemental 
composition 
Suggested identity 
M, S, E C, M 168.065 5.9 15.8 P + N C6H8N4O2 Cyano-metabolite 
(M), E C 287.069 0.9 / 1.1 3.3 / 5.1 P + N C9H13N5O4S Cysteine-Cyano-
metabolite 
M, S C 290.068  11.2 P + N C9H14N4O5S Cysteine ester 
metabolite 
M C 288.053  21.1 P C9H12N4O5S Cysteine ester-
dehydro-metabolite 
M M 186.075  11.5  P + N C6H10N4O3 Amide-metabolite 
M M 228.068 12.2  P  C8H12N4O2S Mercaptoethanol 
adduct pyrrole ring 
M, (S) M 229.075 6.2 14.9 P + (N) C8H11N3O3S Mercaptoethanol-
furazone 
M, S, (E) M 244.063 9.1 19.3 / 19.8 P + N C8H12N4O3S Mercaptoethanol-
Cyano-metabolite 
M, S, E M 324.093 / 
246.079 
6.4 / 6.7 14.9 / 15.8 P C10H20N4O4S2 / 
C8H14N4O3S 
Dimercaptoethanol 
adduct (amide)1 
a
 All metabolites presented contain an intact semicarbazide side-chain.  1 The possibility of a non-covalent 
complex consisting of a mono mercaptoethanol adduct with MW 246 and mercaptoethanol cannot be ruled out. 
 
Addition of mercaptoethanol produces at least 4 different adducts (excluding isomers), comprising 
mono- and – possibly – a di-adduct. The mercaptoethanol metabolite with mass 244 is detected in 
most of the incubates and is likely the fusion product of mercaptoethanol (ME) with the AN-metabolite. 
As for the cysteine incubates, the mercaptoethanol incubates produced a number of ‘unexpected’ 
metabolites. One of them, at RT = 11.5 min has a MW of 186 and its elemental composition matches 
with the CN-metabolite plus water. This corresponds to a compound in which the nitrile (CN) is 
replaced by an amide group (O=C-NH2). Two more interesting metabolites have been identified: one 
with a MW of 228 and another one with MW 229. According to the elemental composition both contain 
a mercaptoethanol substituent, but the former appears to have lost an oxygen atom and the latter a 
nitrogen atom. Possibly these metabolites contain an intact furan or a pyrole ring, respectively. 
Tentative structures are given in Annex III.   
These results indicate that thiol-containing substances (including amino acids, peptides, proteins, 
glutathione) may react in a number of ways with the reactive species formed during NFZ metabolism. 
Some of these products may be quite polar and elute early in the chromatogram. This is in agreement 
with the results obtained in the radio-chromatograms of the incubates, showing high activity at short 
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retention times. When metabolic intermediates react with thiol groups of proteins this will lead to 
tissue-bound adducts, both in vitro and in vivo. 
 
4.3 LC-MS/MS 
In addition to the LC-ToF-MS analysis the extracts obtained from microsomes, S9, as well as E. Coli 
incubates with NFZ and 13C15N2-NFZ were analysed by LC-MS/MS. As a first step the extracts were 
analysed by neutral loss scanning assuming the presence of an intact SEM side-chain in the 
metabolites. Potential metabolites were identified by comparison of spectra obtained for blank, NFZ 
and 13C15N2-NFZ containing incubates. The second step was to verify the obtained results by regular 
LC-MS/MS analysis. 
 
4.3.1 Applied methodology neutral loss scanning 
The semicarbazide side-chain in nitrofurazone and many of is metabolites may produce product ions 
upon collision induced dissociation resulting from the loss of m/z 17 (NH3) and 43 (HN=C=O) neutral 
fragments. Similarly, metabolites originating from 13C15N2-NFZ may undergo specific loss of m/z 17 
(NH3) and 44 (HN=13C=O) neutral fragments. The loss of these fragments may occur in negative as 
well as positive ESI mode. Each compound may produce its specific product ions and with its specific 
abundance. The assumption was made that for most, if not all, semicarbazide-containing substances, 
when subjected to MS/MS fragmentation, one of more product ions will be produced by loss of m/z 17 
or 43/44 in either or both positive and negative mode. By operating the LC-MS/MS instrument in 
neutral loss scanning mode the precursor ions are recorded that produce these typical fragmentations 
(see below).  By comparing the spectra obtained for blank, NFZ and 13C15N2-NFZ incubates, those 
metabolite-related (protonated or deprotonated) precursor ions can be filtered out. The experimental 
procedure is given below. 
 
LC-MS/MS analysis of microsome, S9 and E. Coli incubates: neutral loss scanning 
Extracts of microsome, S9 and E. Coli incubates (obtained according to the protocols described in section 3.1 and 
3.2), including incubates containing surplus cysteine and mercaptoethanol were injected (20 µl) into the LC-
MS/MS system. A  Waters Symmetry C18 (150 x 3.0 mm, 5 µm) column was used at a flow rate of 400 µl/min. The 
metabolites were separated using a linear gradient changing from 100% water to 80% acetonitrile in 15 minutes. 
With this method NFZ was observed at a retention time of 10.9 minutes and the CN-metabolite at 8.4 minutes.  
The mass spectrometer was operated in positive as well as in negative ESI mode. For both modes the cone 
voltage was set at 15 kV and the collision energy at 10 eV. The extracts were scanned (2 sec per scan) for loss of 
m/z 17 and m/z 43/44 fragments. Precursor ions with a mass ranging from 120 to 375 were recorded. For each 
run scans were combined to compose spectra covering 1-min windows. This was done to allow easy visual 
comparison of spectra and providing an indicative retention time of metabolites detected. The composite spectra 
obtained for the NFZ containing incubates were compared with the spectra obtained for the blank incubates. Each 
new precursor ion was marked. The same was done for incubates containing 13C15N2-NFZ. Next the marked 
protonated precursor ions for each composite spectrum of NFZ and that of the corresponding 13C15N2-NFZ 
incubate were compared. In case a correct match was obtained between the samples (a mass increase of 3 or 6 
units in the isotope-labelled incubate spectra) the corresponding precursor ion was flagged.  
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For the metabolites identified in this way the precise retention times were obtained by reinjection of the incubates 
in the LC-MS/MS system. The LC-MS/MS was run in MRM (Multiple reaction monitoring) mode at the transitions 
identified by the neutral loss scanning experiments. For the more prominent metabolites MS/MS scanning in 
product mode was performed at 10 – 20 eV in order to obtain additional information on the chemical structure of 
the metabolites. 
 
In Figure 13 an example is given of the composite mass spectrum collected for the fraction eluting 
between 8 and 9 min of precursor ions undergoing a neutral loss fragmentation of m/z 43 (44 for the 
isotope-labelled compound) of a blank microsome incubate, an incubate with nitrofurazone and an 
incubate with 13C15N2-NFZ. The protonated precursor ion with mass 169 in the NFZ incubate is absent 
in the blank incubate, and has shifted to mass 172 in the 13C15N2-NFZ incubate, indicating the 
presence of a single SEM side-chain. In the same fraction a minor component is observed in the NFZ 
incubate with mass 317 and while a component with mass 323 is present in the 13C15N2-NFZ incubate. 
This mass shift is indicative for a dimeric compound, containing two SEM side-chains.  
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Figure 13: Composite mass spectra of components eluting between 8 and 9 min and undergoing a 
neutral loss of m/z 43 or 44 under positive ESI conditions. (a) and (c) Blank microsome incubate, (b) 
Microsome incubate with NFZ, (d) Microsome incubate with 13C15N2-NFZ. The compound with m/z 169 
in Figure (b) and with m/z 172 in Figure (d) corresponds to the CN-metabolite. Indicated with an arrow 
is a minor dimeric component with mass 317 in the NFZ incubate, and as a component with mass 323 
in the 13C15N2-NFZ incubate.  
 
The metabolites identified by neutral loss scanning were verified by LC-MS/MS analysis of the 
corresponding transitions. In Figure 14 chromatograms of some selected MRM traces are presented 
as an example. The metabolites that were produced in significant amounts were investigated in more 
detail, by means of MS/MS scanning. For a number of compounds the observed fragments and 
a 
b 
c 
d 
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fragmentation pathways provided sufficient information to propose possible chemical structures for 
these metabolites. 
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Figure 14. Chromatograms of blank, NFZ and NFZ + ME S9 incubates. Selected transitions to show 
the presence or absence of (a) a mercaptoethanol furan adduct (M+H+: m/z 230, r.t. 8.2 min), (b) a 
mercaptoethanol pyrrole adduct (M+H+: m/z 229, r.t. 11.0 min), (c) an amide metabolite (M+H+: m/z 
187, r.t. 6.2 min), (d) unreacted nitrofurazone (M+H+: m/z 199, r.t. 10.9 min), (e) the  cyano-metabolite 
(M+H+: m/z 169, r.t. 8.3 min) together with an unknown metabolite at r.t. 3.5 min, and (f) a low 
molecular weight metabolite (M+H+: m/z 126, r.t. 4.1 min) identified as aminofurfural hydrazone. 
 
4.3.2 Identification of metabolites by LC-MS/MS 
By comparing blank, NFZ and 13C15N2-NFZ composite spectra a list of potential metabolites of NFZ in 
microsome, S9 and E. Coli incubates has been compiled (Table 4). From this table it is evident that in 
all incubates a metabolite with mass 168 is produced. Combined with the information collected with 
the LC-ToF-MS and the standard synthesized by Eurofins (Dr. S. Weigel and Dr. R. Gatermann), this 
metabolite can be positively identified as the CN-metabolite. In the microsome incubates also a minor 
metabolite with mass 166 eluting at 8.9 min is observed. The obtained MS/MS spectrum is in 
accordance with the acrylonitrile-metabolite (see also section 4.3.3). This metabolite is not present in 
detectable amounts in the S9 and E.Coli incubates.  
 
 
 
 
 
a 
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e 
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Table 4. Potential metabolites of nitrofurazone, detected by LC-MS/MS neutral loss scanning of 
microsome, S9 fraction and E. Coli incubates, retention times, observed neutral losses in positive and 
negative ESI and proposed molecular identities of metabolites.  
Neutral loss fragments 
m/z 17 m/z 43/44 
Microsome 
S9 fraction 
E. Coli 
Observed 
precursor  
nominal mass  
Retention 
time (min) 
Positive/Negative 
SEM  side-
chain 
Suggested identity 
M, S 125 4.1 P  Single1 Aminofurfural hydrazone 
M, S, E 168 8.3  P, N Single Cyano-metabolite 
M 166 8.9   N Single Acrylonitrile-metabolite 
S, E 186 6.2 P N Single  Amide-metabolite 
M 316 7.8 / 8.2 P P, N Double Dimeric compound  
E 332 9.3 / 9.7 P N Double Dimeric compound  
E 342 11.3 P N Double Dimeric compound 
1
 Mass increase of 2 units observed in the 13C15N2-metabolite 
 
A metabolite with low molecular mass (125) was detected in microsome and S9 incubates at a 
relatively short retention time. A mass increase of only 2 units was observed for the 13C15N2-NFZ 
incubates indicating an incomplete SEM side-chain (loss of the terminal O=C-NH2 / O=13C-NH2 group). 
MS/MS fragmentation (10 eV) of the protonated species (mass 126) yielded two fragments with mass 
109 (loss of 17, NH3) and mass 81 (additional loss of 28, CO) (Figure 15). MS/MS fragmentation of the 
isotope-labelled analog (mass 128) yielded m/z 111 and 83 fragments, respectively. Upon 
fragmentation the mass difference of 2 units is conserved, indicating that fragmentation occurs at the 
furan side of the molecule. Possible structures of the precursor molecule include a truncated CN-
metabolite or an aminofurane metabolite (aminofurfural hydrazone). The latter is more probable 
because the precursor ion loses a fragment with mass m/z 17 (NH3) instead of m/z 27 (HCN) under 
the conditions used. Furthermore, this NH3 group does not originate from the SEM part of the 
molecule as this would have resulted in a loss of m/z 18 (15NH3) for the 13C15N2-NFZ incubate, but a 
regular loss of m/z 17 is observed for this compound instead. Probably the furan derivative with mass 
109 rearranges to a more stable seven membered ring system. The fragment with mass 81 probably 
corresponds to a protonated pyridazine molecule. 
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Figure 15: MS/MS spectra produced (collision energy: 10 eV) from the metabolite with MW 125 
(aminofurfural hydrazone) and its isotope-labelled analog. Probable structures of the fragments are 
indicated. 
Similarly, a metabolite eluting at 6.2 min and with mass 186 was observed in S9 and E. Coli incubates. 
A mass of 186 could correspond to a ring-opened metabolite with a terminal amide group instead of a 
cyano group. This metabolite was also detected by LC-ToF analysis. To further elucidate the structure, 
the protonated molecule was fragmented (10-20 eV) (Figure 16). At low collision energy the major 
fragments are m/z 170 (loss of 17, NH3) and m/z 127 (additional loss of 43, HNCO). At higher collision 
energy the m/z 127 fragment loses a fragment with mass 28 (loss of CO or N2) to 99 and further to 71 
(loss of 28, CO or N2). The corresponding fragments (data not shown) for the isotope-labelled analog 
are: m/z 190 produces 173 (loss of 17, NH3) and m/z 129 (additional loss of 44, HN13CO). Furthermore 
two products are formed with mass 99 (loss of 30, 15N2) and 101 (loss of 28, CO) and a fragment with 
mass 71 (loss of 28, CO and loss of 30, 15N2). In negative ESI mode the deprotonated molecule (m/z 
185) produces fragments with mass 170 (loss of 18, H2O), mass 142 (loss of 43, HNCO), mass 124 
(loss of 18, H2O from the m/z 142 fragment), and mass 96 (loss of 28, N2, from the m/z 124 fragment). 
The fragments observed for the isotope-labelled analog are in accordance with the proposed 
structures. All data collected point to an open-chain amide metabolite.  
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Figure 16: MS/MS spectra obtained for the metabolite with MW 186 and retention time of 6.3 min. 
Probable structures of the fragments are indicated. 
 
Several dimeric compounds were detected in the microsome and E. Coli incubates. Peak intensities 
were quite low, however, especially when compared to the ToF-MS results (perhaps the loss of m/z 17 
or 43 fragments is not very prominent for these compounds). The dimer with mass 312 formed in 
microsome incubates was also detected by LC-ToF-MS. The same is true for the MW 332 dimeric 
compound detected in the E. Coli incubate. The dimer with mass 366 observed in the ToF analysis of 
microsomal incubates was not detected by neutral loss scanning. 
The same methodology was applied for incubates to which surplus cysteine or mercaptoethanol was 
added. In Table 5 and Annex IV the results are compiled.  In most incubates the CN-metabolite could 
be detected. Its formation is reduced in the cysteine incubates. Similarly, the presence and identity of 
the low-molecular mass (125) metabolite could be confirmed. Dimeric compounds were hardly 
detected, which is in good agreement with the ToF-MS results. The formation of these compounds is 
strongly reduced by the presence of excess cysteine or mercaptoethanol.  
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Table 5. Potential metabolites of nitrofurazone, detected by LC-MS/MS neutral loss scanning of 
microsome, S9 fraction and E. Coli incubates in the presence of cysteine and mercaptoethanol. The 
observed retention time, neutral loss in positive and negative ESI and proposed molecular identity of 
metabolites is given. 
Neutral loss 
fragments 
m/z 17 m/z 43/44 
Microsome 
S9 fraction 
E. Coli 
Addition of 
Cysteine/ 
mercapto-
ethanol 
Observed 
precursor 
mass (m/z) 
Retention 
time 
(min) 
Positive/Negative 
SEM  
side-
chain 
Suggested identity 
M,S C, M 125 4.1 P  Single1 Aminofurfural hydrazone 
M, S, E (C), M 168 8.3  P, N Single Cyano-metabolite 
M, S C 290 8.4 N N Single Cysteine ester-metabolite 
M, S C 288 9.8 / 10.3 N P Single Cysteine ester-dehydro-
metabolite 
M, S, E M 168 3.5 P P Single CN-metabolite analog 
M, S, E M 186 6.2 P N Single  Amide-metabolite 
M, S M 229 8.2 P P Single Mercaptoethanol-
furazone 
M, S, E M 228 11.0 P  P, N Single  Mercaptoethanol adduct 
pyrrole ring 
E M 332 9.3 / 9.7 P N Double Dimeric compound 
1
 Mass increase of 2 units observed in the 13C15N2-metabolite 
 
Several new metabolites were found in both cysteine and mercaptoethanol incubates. At least three 
different cysteine adducts were observed in both microsome and S9 incubates. However, E. Coli 
incubates failed to produce detectable amounts of cysteine adducts. The observed masses (288 and 
290) and the prominent loss of m/z 17 (cysteine-NH3) in negative mode are indicative for cysteine 
adducts. Interestingly, the synthesized standard of the cysteine-CN-metabolite (gift of Dr Weigel and 
Dr. Gatermann of Eurofins) does not match with any of these metabolites: the standard has a retention 
time of only 4 min and a mass of 287 (see section 4.3.3). A mass difference of 1 or 3 units indicates 
the loss of a NH group (or exchange to an O group). Tentative structures of the cysteine adducts are 
given in annex IV. 
The mercaptoethanol incubates produced a variety of metabolites. The amide metabolite with mass 
186 is abundantly formed. A metabolite with mass 168 was observed in all incubates at short retention 
time (3.5 min). As yet, the identity of this metabolite remains to be elucidated, but its short retention 
time suggests a polar nature. In conjunction with the LC-ToF results, all mercaptoethanol incubates 
produced a metabolite with mass 228, while in the microsome and S9 incubates also a metabolite with 
mass 229 was produced (but clearly absent in E. coli). The mass difference of 1 unit indicates the 
difference between an O and an NH group. For the metabolite with MW 229, the MS/MS fragmentation 
spectra collected point to a furazone compound in which the nitro-group has been substituted for a 
mercapoethanol substitutent (data not shown). The metabolite with MW 228 probably contains a 
similar structure, but with a pyrrole ring instead of a furan ring. These two metabolites were also 
identified by LC-ToF-MS (section 4.2.2 and Annex IV) 
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The list of tentatively assigned metabolites suggests that sulphur containing substances react with the 
intact furan ring (e.g. by attack on the nitro or amino group) rather than with the double bond of the 
acrylonitrile metabolite. The expected CN-metabolite containing a mercaptoethanol adduct with MW of 
244 was not detected by LC-MS/MS (but it was detected in microsome and S9 incubates by LC-ToF-
MS). It can not be excluded that acrylonitrile adducts are not detected because they do not produce 
the selected neutral loss fragments. Even though the structures proposed remain speculative, it can 
be concluded that there are several positions in the nitrofurazone molecule that may react with free 
thiol groups and may lead to a variety of tissue-bound and free metabolites.  
 
4.3.3 Verification of synthesized metabolites by LC-MS/MS 
The final step in the determination of potential metabolites in the microsome, S9 and E. Coli incubates 
comprised the analysis of selected compounds by LC-MS/MS.  As has been discussed in section 
4.3.2, the neutral loss scanning experiments have resulted in the identification of a number of potential 
metabolites. It should be noted that metabolites which do not yield a detectable neutral loss 
fragmentation of m/z 17 or 43 in either positive or negative mode are missed. The ToF-MS 
experiments indicated that some metabolites are formed that do not yield one of these neutral loss 
fragmentations (or in low abundance only). Unfortunately the ToF-MS experiments yield accurate 
mass and elementary composition data on the parent molecule only and not on potential product ions.  
In addition to this, a number of nitrofurazone metabolites have been provided by the partner involved 
in lot 2, (Dr. Gatermann, Eurofins, Germany). Several of these metabolite standards have been 
incorporated in this study: the cyano-metabolite (CN-metabolite), acrylonitrile metabolite (AN-
metabolite), glutathione-cyano-metabolite (GSH-CN-metabolite) and cysteine-cyano-metabolite (Cyst-
CN-metabolite) were investigated by LC-MS/MS.  
The partner involved in lot 2 had indicated that the sulphur-adducts of the CN-metabolite synthesized 
are unstable and react in the presence of a strongly basic alkyl amine like pyrrolidine or piperidine 
(poster presented by S. Weigel et al at 2nd Int Symp. on Recent Advances in Food Analysis, Prague, 
November 2-4, 2005). In order to study this reactivity in some detail (and to investigate the usefullness 
of piperidine as a trapping reagent of sulphur adducts in vitro and in vivo) a piperidine metabolite was 
synthesized in-house by reaction of a 0.2% solution of piperidine in water with a solution of the GSH-
CN-metabolite or cyst-CN-metabolite. The available metabolites together with analytical standards of 
NFZ and GSH were analysed in positive and negative electrospray mode (Table 6 and 7): 
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Table 6: Analysis of nitrofurazone and synthesized metabolites by positive electrospray MS(/MS) 
Metabolite [M+H]+ 
(m/z) 
Cone  
(V) 
Collision 
Energy (eV) 
Fragments 
(m/z) 
CN-metabolite1 169.1 15 15 
8 
81.7 
126.0 
AN-metabolite1 167.1 15 10 
8 
67.6 
124.0 
Cyst-CN-metabolite1 288.2 15 10 
10 
75.6 
213.0 
GSH-CN-metabolite1 474.3 15 15 
15 
270.1 
345.1 
NFZ2 199.1 15 13 
13 
156.0 
182.0 
GSH2 308.2 25 15 
15 
162.0 
179.0 
Piperidine-metabolite3 225.1 25 16 
16 
138.0 
208.1 
1 Provided by the partner involved in lot 2 (Dr Gatermann, Eurofins, Germany). 2 Included for completeness  
3
 Standard obtained by reaction of GSH-CN-metabolite with piperidine 
 
Table 7: Analysis of nitrofurazone and synthesized metabolites by negative electrospray MS(/MS) 
Metabolite [M-H]+ 
(m/z) 
Cone  
(V) 
Collision 
Energy (eV) 
Fragments 
(m/z) 
CN-metabolite 167.1 10 8 
8 
124.0 
140.0 
AN-metabolite 165.1 15 10 
10 
94.7 
122.0 
Cyst-CN-metabolite1 286.2 10 10 
10 
122.0 
165.0 
GSH-CN-metabolite2 472.2 15 15 306.2 
NFZ 197.1 20 10 
10 
124.0 
150.0 
GSH 306.2 20 20 
20 
128.0 
143.0 
Piperidine-metabolite2 223.1 25 15 94.7 
1 The cyst-CN-metabolite proved very labile under the MS conditions used. Even at low cone voltage in-source 
fragmentation producing the m/z 165 fragment is prominent. 2 Only one fragment was observed in neg ESI.  
 
The LC-MS/MS method described in section 4.3.1 for the neutral loss experiments was used for the 
analysis of the above mentioned metabolites. Typical retention times and ion ratios obtained for the 
metabolites are shown in Table 8. Two peaks were observed for the AN-metabolite, possibly 
representing the cis and trans isomers. It was noted that aqueous solutions of the standards were 
quite unstable. At pH 7 most of the GSH-CN-metabolite, the cyst-CN-metabolite as well as the AN-
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metabolite(s) had decomposed to unidentified products within 24 h. At pH 3 (1% acetic acid solution) 
the standards were stable. The CN-metabolite proved to be stable in solution in a pH range of 2 to 12. 
A stability study indicated that solutions of the CN-metabolite in water ware stable for at least 4 weeks 
at 4oC.  
 
Table 8: Retention times of the synthesized metabolites and ion ratios of the product ions described in 
Tables 6 and 7. 
Component Retention time 
(min) 
Ion ratio (pos 
ESI) 
Ion ratio (neg ESI) 
CN-metabolite 8.2 60% 41% 
AN-metabolite 9.6 (major)  
8.8 (minor) 
23% 
24% 
60% 
86% 
GSH-CN-metabolite 8.5 56% Only one fragment detected 
Cyst-CN-metabolite1 5.3 23% 65% 
NFZ 10.8 58% 83% 
GSH 3.4 86% 51% 
Piperidine-metabolite 10.2 83% Only one fragment detected 
1
 Low sentisitivity in neg ESI mode due to extensive in-source fragmentation. 
 
The formation of the piperidine-metabolite was investigated in some detail at RIKILT. When the GSH-
CN; cyst-CN or the AN-metabolite are added to a solution of 0.2% piperidine in water (pH = 12), the 
corresponding piperidine metabolite is formed instantaneously. At lower pH, the formation slows down, 
requiring more than 24 h at pH 7. At a pH lower than 7 no piperidine metabolite is formed at all.  
In Figure 17 a tentative mechanism is depicted by which sulphur-containing metabolites can be 
transformed into a piperidine containing metabolite. Piperidine is likely acting both as base as well as 
the nucleophilic reagent. The driving force of this reaction is the formation of the relatively stable 
enamine derivative. It can be rationalized that 2-adducts are labile to basic conditions and prone to 
lose the sulphur substituent. In contrast 3-adducts are predicted to be more stable to basic conditions 
as the sulphur substituent cannot be cleaved very easily.  
The stability of the piperidine metabolite at various pH was investigated as well. It was noted that at 
acidic pH the piperidine metabolite degrades quite rapidly. This is not surprising: enamines are 
hydrolyzed under acidic aqueous conditions (March, 1985). 
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Figure 17: Tentative mechanism of the formation of a piperidine metabolite from sulphur-containing 
metabolites.  
 
The microsomal, S9 and E.coli incubates were analysed for the presence of the selected metabolites 
by means of the MS conditions described in Table 5 and 6. NFZ and the CN-metabolite were positively 
identified in these incubates, thus confirming the results already obtained in sections 4.2.2 and 4.3.2. 
In the microsomal preparation a small amount of the AN-metabolite was identified (see also section 
4.3.2). Interestingly, the synthesized standard exists of two compounds (cis and trans isomers?), while 
the microsome extract contains only one of them (likely the cis isomer). No evidence was found for the 
presence of the cyst-CN and GSH-CN metabolites in any of the incubates. This may indicate that they 
are formed in low concentrations only, or that their stability is rather limited.  
A number of incubation extracts was treated with a 0.2% piperidine solution in order to produce the 
piperidine metabolite. Only trace amounts of this metabolite were formed, corroborating the finding 
that sulphur containing addition products to the AN metabolite are present in very low concentrations. 
 
4.4 Overall discussion of results 
The chemical reduction of nitrofurazone to its amino derivative has been described as early as 1957 
by Austin. It was noted at the time that aminofurazone is a rather unstable compound, which slowly 
rearranges to form the corresponding CN-metabolite. Interestingly, the aminofurans produced upon 
reduction from other nitrofurans, like furazolidone and furaltadone were quite stable compared to 
nitrofurazone (Ebertino et al, 1962). The metabolism of nitrofurazone has been studied in limited detail 
only. Early reports mention the formation of the CN-metabolite as a major metabolite (Beckett and 
Robinson, 1957; Tasumi et al, 1975). The CN-metabolite was also found in the urine of rats 
administered with NFZ (Yeung et al, 1983). Based on this information combined with what is known for 
the metabolism of FZD, an overview of potential metabolites of NFZ was made. This overview is 
presented in Annex I.  
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Wrapping up the results obtained for the analysis of the microsome, S9 and E. Coli incubates, it can 
be concluded that several metabolites are produced. The chemical structures of these metabolites 
could be established in varying detail, depending on the availability of a synthesized standard or on 
the mass spectrometric data collected. The combined information of high-resolution ToF mass spectral 
data, MS/MS fragmentation patterns and the comparison of spectra of unlabelled and isotope-labelled 
analogs provided substantial evidence for the structure elucidation of several new metabolites. Three 
of them (CN-metabolite, amide metabolite and aminofurfural hydrazone metabolite) are of interest for 
further investigation. It should be noted that only the CN-metabolite is detected in all test systems and 
under all circumstances. The other two were detected in two out of three incubation systems. Another 
advantage of the CN-metabolite is that a synthesized standard is available. The microsome incubates 
produce several dimeric compounds, which are of limited interest for in vivo systems. A number of 
cysteine and mercaptoethanol adducts identified are only formed in detectable amounts when large 
amounts of the thiol component are added to the incubates.  
The next step in the selection of an alternative marker for semicarbazide will be the study on the 
occurrence and depletion characteristics of the three selected metabolites. They will be investigated in 
incurred materials, in conjunction with the development of a LC-MS/MS confirmatory method for the 
metabolite that is finally chosen. The research conducted on this subject will be described in Chapter 
5. 
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5 LC-MS ANALYSIS OF INCURRED MATERIALS AND DEVELOPMENT OF A LC-MS/MS 
CONFIRMATORY METHOD 
 
5.1 LC-MS analysis of incurred materials 
Having identified the major metabolites formed in in vitro incubates, the attention was directed to the 
analysis of incurred materials. Porcine muscle and liver samples were provided by the partner involved 
in lot 3, Dr Cooper of Chemical Surveillance Department, Veterinary Sciences Division, Belfast. These 
samples had originally been collected in the framework of the FoodBRAND FP5 project. Pigs had 
received 400 mg/kg nitrofurazone in feed for 10 days and were slaughtered at various withdrawal 
times. The muscle and liver samples of week 0 and week 6 were selected for investigation by LC-
MS/MS and LC-ToF-MS. The muscle samples of week 0 at the time of collection contained approx. 
2000 µg/kg tissue-bound SEM (plus an unknown amount of extractable metabolites!), the samples of 
week 6 contained 250 µg/kg. For liver the concentrations determined were 2500 and 40 µg/kg tissue-
bound SEM at week 0 and 6, respectively.  
Of each sample 500 mg of tissue was extracted with 2 ml water, centrifuged and filtered through a 
0.45 µm acrodisc filter. The samples of week 6 were also spiked with a mix of metabolites at 500 µg/kg 
before extraction. 
The samples were injected into the LC-ToF-MS and run with LC-gradient system 2, optimised for 
moderately polar metabolites. MetAlignTM software was used to analyse the obtained data from the LC-
ToF-MS experiments. The full scan data of week 0 and week 6 were compared. MetAlignTM indicated a 
substantial number of differences between the two data sets. This could be explained, at least in part, 
by the fact that the tissues of two different animals were compared, which can be expected to differ 
more than two in vitro incubates. Except for the CN-metabolite, none of the obtained accurate mass 
data for these peaks could be correlated to previously identified metabolites. Only the CN-metabolite 
could be positively identified in the week 0 muscle tissue sample. If present, the concentration of other 
potential metabolites apparently is too low to allow detection under the conditions applied.  
The same extracts were also subjected to LC-MS/MS analysis on a Micromass Micro system (Figure 
18). Only two metabolites were detected In the muscle extracts of week 0: the CN-metabolite at a 
concentration of approx 500 ng/g, as well as the metabolite assigned as aminofurfural hydrazone with 
MW 125. The concentration of the latter cannot be determined as an analytical standard is not 
available. Both metabolites are not detectable in the week 6 extract. The amide metabolite as well as 
any of the other reference metabolites were not present in detectable concentrations in both week 0 
and 6 extracts. Although the muscle tissue extracts contained large amouts of gluthatione (in excess of 
10 µg/g, data not shown), the GSH-CN-metabolilte was not detected (detection limit: 25 ng/g). 
Additional analysis of the extracts on the more sensitive Micromass Ultima system revealed traces of 
NFZ (less than 5 ng/g) and of the GSH-CN-metabolite (5 ng/g) to be present in the week 0 sample 
(data not shown). No detectable amounts of the AN-metabolite and the cyst-CN-metabolite were 
found. Analysis of the spiked sample showed that the recovery of the latter two metabolites was very 
low. These metabolites either are not extracted by the extraction procedure used or are too unstable to 
be recovered. In the week 6 sample extracts as well as in the liver extracts concentrations of each of 
the metabolites were below or close to the limit of detection. Apparently the metabolites selected 
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accumulate to a lesser extent in liver tissue than in muscle tissue. It is possible that these metabolites 
are formed in the liver, but that they are quickly transformed to other products due to enzymatic and 
chemical action. 
   
 
Figure 18: LC-MS/MS analysis of incurred porcine muscle tissue extracts of week 0 and 6. Some 
selected transitions are shown as an example: (a) GSH-CN-metabolite, (b): amide metabolite, (c) and 
(d) two MRM transitions of the CN-metabolite, (e) and (f) two MRM transitions of the 125-MW 
metabolite.  
 
To test for the presence of sulphur-containing metabolites, the aqueous muscle extracts were treated 
with piperidine to a final concentration of 0.5%. The spiked sample of week 6 was used to check the 
complete conversion of the sulphur-containing metabolites into the piperidine derivative. As expected 
the CN-metabolite proved stable under the action of piperidine. A small amount of piperidine derivative 
(estimated to be not more than 25 ng/g) was detected in the week 0 extract. This concentration is 
somewhat higher that accounted for by the GSH-CN-metabolite (5 µg/kg), indicating the presence of 
other, unidentified, sulphur-containing adducts or metabolites.  
It can be concluded that the CN-metabolite is detected in substantial amounts (approx. 500 µg/kg) in 
porcine muscle tissue during medication with nitrofurazone. In liver tissue the concentration is 
significantly lower. The low molecular weight metabolite (aminofurfural hydrazone) is present in a 
substantial amount in muscle tissue as well, but by lack of a standard it can not be quantified. All other 
targeted metabolites, if detected at all, are present in muscle as well as liver tissue only at extremely 
low concentrations, even during medication. It can not be excluded that adducts are formed by 
reaction of thiol-containing substances (amino acids, gluthatione, proteins), but these adducts may be 
of limited stability under the extraction conditions used. 
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5.2 Development of a confirmatory LC-MS/MS method for the cyano-metabolite of NFZ 
All the experiments and work described in chapters 3 to 5 point to one single conclusion: the most 
likely candidate metabolite as an alternative to the current method of analysis is the CN-metabolite. 
The aminofurfural metabolite could be an interesting alternative only if method development fails for 
the CN-metabolite. All other metabolites (tentatively) identified are either metabolites formed in only 
one assay (e.g. dimeric compounds in the microsome incubates), or appear to be rather unstable and 
transient under the experimental conditions used (e.g. AN-metabolite) or are present in only very low 
concentrations even at zero-withdrawal time (e.g. GSH-CN-metabolite). The reaction with piperidine 
produces some derivatised product, but the amounts are relatively small compared to that of the CN-
metabolite and therefore do not constitute a viable alternative. Hence, it was concluded that the CN-
metabolite is the mostly likely alternative to SEM for the development of a confirmatory LC-MS/MS 
method suitable for official control.  
 
To explore the possibility of a selective and sensitive analytical method for the determination of the 
CN-metabolite in muscle tissue, an improved extraction protocol was developed as described below. 
 
Sample preparation procedure for the analysis of the CN-metabolite  
One gram of sample is extracted with 10 ml of phosphate buffer pH 7 for 1 hour. The sample is centrifuged (10 
min at 4000 rpm) and the supernatant is applied to a pre-conditioned Waters Oasis HLB 60 mg, 3 ml cartridge. 
The cartridge is washed with 3 ml water and eluted with 3 ml methanol. After evaporation to dryness the residue is 
reconstituted in 500 µl 0.2% formic acid.  Analysis is performed by LC-MS/MS (Micromass Ultima) in negative ESI 
mode. Chromatographic conditions were applied as described in section 4.3.3. 
 
To optimise extraction recovery several solvents and buffers of various pH were tested. Best results 
were obtained with a neutral or slightly acidic phosphate buffer. A single extraction with 10 ml of buffer 
followed by SPE over a Waters Oasis HLB column proved to give the most reliable results, with an 
overall recovery of 65%.  
Several instruments (Micromass Ultima and Micromass Micro) and positive versus negative 
electrospray mode were compared to determine the optimal conditions for the analysis of the CN-
metabolite. Best results were obtained on a Micromass Ultima instrument with negative ESI. 
The method was applied to the incurred porcine materials obtained from VSD. Two muscle tissue 
samples of week 0 and one sample of week 1, 2, 3, 4 and 6 as well as a liver and a kidney sample of 
week 0 were analysed in duplicate. Quantification was performed against a matrix matched standard 
curve. The results are presented in table 8. At zero withdrawal time substantial amounts of the CN-
metabolite are present in muscle tissue (around 500 µg/kg). The concentration in liver (20 µg/kg) and 
kidney (40 µg/kg) on the other hand is considerably lower. After one week of withdrawal the levels in 
muscle tissue have dropped to only 3 µg/kg, which is close to the limit of detection (2 µg/kg). There is 
no direct link between the amounts of tissue-bound SEM present and that of the CN-metabolite. The 
concentration of the CN-metabolite drops much more quickly than that of tissue-bound SEM. This 
indicates that when tissue-bound SEM is removed from the protein, it is not released in the form of the 
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CN-metabolite. Further improvement of the analytical method will be required to determine if the low 
concentrations detected of the CN-metabolite in the muscle samples of week 2 to 6 are real or just an 
artefact.  
 
Table 8: Analysis of incurred porcine materials by LC-MS/MS: determination of the CN-metabolite. 
Results obtained by duplicate analysis. 
Matrix Sample ID Week Content 
(µg/kg) 
Tissue-bound 
SEM (µg/kg)a 
Remark 
Porcine Muscle 0309845 0 403 ± 15 2000 Also NFZ detected at 7 µg/kg 
 0309846 0 722 ± 52 1781 Also NFZ detected at 4 µg/kg 
 0309859 1 3.0 ± 0.2 1006  
 0309869 2 0.8 ± 0.1 450 Only one product ion detectedb 
 0309881 3 1.1 ± 0.3 499 Only one product ion detectedb 
 0309893 4 0.9 ± 0.7 477 Only one product ion detectedb 
 0309905 6 1.2 ± 0.2 241 Only one product ion detectedb 
Porcine Liver 0309845 0 21.4 ± 0.4 2668  
Porcine Kidney 0309845 0 41.4 ± 3.6 3599  
a
 As determined by VSD. b The identity of the analyte could not be confirmed 
 
In conclusion, the CN-metabolite, being the major metabolite detected in microsomal and E. Coli 
preparations, is also formed in vivo. Accumulation during medication largely occurs in muscle tissue. In 
liver and kidney tissues only low concentrations are observed, probably the metabolite is quickly 
metabolised to other yet unidentified metabolites. Although depletion in muscle tissue is relatively 
quick compared to the persistent tissue-bound metabolites, its presence can be detected up to one 
week after the end of medication. It should be realized that many authorized veterinary drugs have 
depletion half-lives ranging from only a few hours up to a few days at the most. This is also the case 
for other banned substances like nitroimidazoles and various growth promoting agents. It is therefore 
recommended that the LC-MS/MS method described for the CN-metabolite in this study should be 
further improved and that the substance should be made available as a reference material (including 
an isotopically-labelled analogue as IS). 
 
 45 
6 CONCLUSIONS 
 
At the start of the project a considerable uncertainty in completing the project was foreseen, originating 
from the fact that the analyte was unknown and hence no realistic estimate of the difficulty of this task 
could be made.  
Due to the fact that the synthesis of 14C-labelled standards and a 13C15N2-labelled standard was 
successful, the metabolic pathway of nitrofurazone could be elucidated in considerable detail from in 
vitro experiments using chicken liver microsomes and S9 fraction, and Escherichia Coli ATCC 8739.  
The combination of high-resolution ToF mass spectrometry with MetAlignTM software for analysis of  
the full scan mass data proved very fruitfull in the detection and identification of a substantial number 
of metabolites. Based on the detected accurate mass elemental compositions could be derived for a 
number of potential metabolites. LC-MS/MS analysis of the incubates by means of neutral loss 
scanning yielded complementary information to LC-ToF-MS. Many of the metabolites detected by LC-
ToF-MS were also identified by LC-MS/MS. MS/MS fragmentation yielded important information on the 
chemical structure of some of the newly identified metabolites.  
The major metabolite identifed was the cyano-metabolite. It was detected in all test systems and under 
all circumstances. In addition, two other interesting metabolites were identified: a low molecular weight 
metabolite (aminofurfural hydrazone) in microsome and S9 incubates and an amide metabolite in S9 
and E. Coli incubates. Several dimeric compounds were also detected in the microsome and E. Coli 
incubates, but these are of limited interest for in vivo systems. Furthermore, several cysteine and 
mercaptoethanol adducts were (tentatively) identified. However, these metabolites were only formed in 
detectable amounts when large amounts of the thiol component were added to the incubates. Based 
on the experiments conducted and the metabolites identified it can be concluded that several modes 
of metabolism occur simultaneously in the in vitro systems. The formation of the CN-metabolite is in 
good agreement with what is known from the metabolism of furazolidone and nitrofurazone. The CN-
metabolite could therefore be considered as a potential alternative marker for NFZ.  
Analysis of incurred material showed unequivocally that the CN-metabolite is present in substantial 
amounts (approx. 500 µg/kg) in porcine muscle tissue during medication with nitrofurazone. In liver 
tissue the concentration was significantly lower. Probably the metabolite is quickly metabolised to 
other yet unidentified metabolites. Of the other metabolites selected, the aminofurfural hydrazone 
metabolite was qualitatively detected in incurred muscle tissue at zero withdrawal time. All other 
potential metabolites, if detected at all, were present in muscle as well as liver tissue only at low 
concentrations, even at zero withdrawal time. It could not be excluded that adducts are formed by 
reaction of thiol-containing substances (amino acids, gluthatione, proteins), but these adducts may be 
of limited stability under the extraction conditions used, or extraction recoveries for these compounds 
may be low. 
Accumulation of the CN-metabolite largely occurs in muscle tissue during medication. In muscle tissue 
it is detectable for at least one week after the end of medication. Although depletion in muscle tissue is 
relatively quick compared to the persistent tissue-bound adducts, its presence can be detected up to 
one week after the end of medication. It should be realized that many authorized veterinary drugs 
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have depletion half-lives ranging from only a few hours up to a few days at the most. This is also the 
case for other banned substances like nitroimidazoles and various growth promoting agents.  
 
Overall it can be concluded that the main objective of the project, being “The identification and 
structure elucidation of an alternative indicator (marker residue) for nitrofurazone use in animal derived 
food products” has been completed successfully. The second objective, “Development of a routine 
method of analysis to identify this marker that fulfils the requirements of Decision 2002/657/EC”, could 
not be completed fully, due to the time-consuming procedure to elucidate the metabolic pathway of 
nitrofurazone. Nonetheless, the preliminary results obtained indicate that such a method can be 
developed for the CN-metabolite of NFZ. It is recommended that a future prolongation of this research 
should include improvement of the LC-MS/MS method for the CN-metabolite and that the substance 
should be made available as a reference material (including an isotopically-labelled analogue as IS).  
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